Healthy AdultFIND T1DNCT07663136
Finding Immune Nascent Type 1 Diabetes
A study testing phone call and email/mail in people with Healthy Adult and Type 1 Diabetes (T1D), run by Indiana University at 1 site in United States.
Trial summary
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. Read more about this study
- Who is it for?
- Ages 1 year to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult, Type 1 Diabetes (T1D)
- What is being tested?
- phone call and email/mail
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,800 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Jul 2026to Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 99 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Participant must be in Indiana Biobank
- Participant must be able to provide consent
- Ages 1-99 including pregnant women
Who cannot join
- Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
- While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Indiana University School of Medicine
Indianapolis, Indiana, 46202
Emily K Sims, MD
About this study
Official title: Finding Immune Nascent Type 1 Diabetes (FIND T1D)
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:
What form of recruitment communication is most effective for completing a type 1diabetes home screening kit?
Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).
Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.
- Conditions
- Healthy Adult, Type 1 Diabetes (T1D)
- Being tested
- phone call, email/mail
- Keywords
- type 1 diabetes home screening kit, type 1 diabetes
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
phone callBehavioural
Recruitment through phone call
email/mailBehavioural
Recruitment through email and mail
| Study group | Role | What they receive |
|---|---|---|
| Low-touch intervention | Experimental | Not described Receives: Behavioral: email/mail |
| High-touch intervention | Experimental | Not described Receives: Behavioral: phone call |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rates of Returned Home Screening Kits
The number of returned screening kits versus the number that were not returned by consented participants.
Measured: From enrollment to the end of study at 3 years.
Rates of Consent
The number of participants who consent versus the number of participants who do not consent.
Measured: From enrollment to the end of study at 3 years.
Secondary outcomes (3)
Percent of Kits with Adequate Blood Volume
Measured: From enrollment to the end of study at 3 years.
Rates of Returned Home Screening Kits
The number of returned screening kits versus the number that were not returned by consented participants. Some of which will receive information that they may be at increased risk of type 1 diabetes.
Measured: From enrollment to the end of study at 3 years
Rates of Consent
The number of participants who consent versus the number of participants who do not consent. Some participants will receive information that they may be at increased risk of type 1 diabetes.
Measured: From enrollment to the end of study at 3 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2026
- Study start28 Jul 2026
- Primary completionJun 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 3,800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Collaborators
- Sanofi
- Responsible party
- Principal investigator, Emily K. Sims, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07663136
- Sponsor's protocol ID
- 31119
- Acronym
- FIND T1D
- Status last verified
- Jun 2026
- First submitted
- 17 Jun 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Participant results will be shared as summary data but because participants declining consent have not agreed we will not provide individual level data.
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Finding Immune Nascent Type 1 Diabetes (FIND T1D)
- ClinicalTrials.gov ID
- NCT07663136
- Acronym / sponsor ID
- FIND T1D / 31119
- Conditions
- Healthy Adult, Type 1 Diabetes (T1D)
- Keywords
- type 1 diabetes home screening kit, type 1 diabetes
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 3,800 participants (estimated)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Collaborators
- Sanofi
- Study start
- 28 Jul 2026 (actual)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 23 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:
What form of recruitment communication is most effective for completing a type 1diabetes home screening kit?
Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).
Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Low-touch intervention | Experimental | Behavioral: email/mail |
| High-touch intervention | Experimental | Behavioral: phone call |
Who may qualify
- Ages
- 1 year to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Participant must be in Indiana Biobank
- Participant must be able to provide consent
- Ages 1-99 including pregnant women
Key exclusion criteria (2 listed)
- Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
- While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| phone callRecruitment through phone call | Behavioural | High-touch intervention |
| email/mailRecruitment through email and mail | Behavioural | Low-touch intervention |
Primary outcome
Rates of Returned Home Screening Kits
Time frame: From enrollment to the end of study at 3 years.
The number of returned screening kits versus the number that were not returned by consented participants.
Rates of Consent
Time frame: From enrollment to the end of study at 3 years.
The number of participants who consent versus the number of participants who do not consent.
3 secondary outcomes
Percent of Kits with Adequate Blood Volume
Time frame: From enrollment to the end of study at 3 years.
Rates of Returned Home Screening Kits
Time frame: From enrollment to the end of study at 3 years
Rates of Consent
Time frame: From enrollment to the end of study at 3 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Individual participant dataSharing planned: No. Participant results will be shared as summary data but because participants declining consent have not agreed we will not provide individual level data.
Related trials for Healthy Adult
RecruitingPhase 1
A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.
Healthy Adult
RecruitingPhase 1
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
EBV
Active, not recruitingPhase 1/2
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
RSV Infection, Human Metapneumovirus Infection
Recruiting
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Healthy Volunteer
Not yet recruiting
Performance Evaluation of the OCUTOP Hand-held Corneal Topographer
Corneal Topography, Dry Eye Syndromes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing phone call and email/mail in people with Healthy Adult and Type 1 Diabetes (T1D), run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maureen Mullen Montagano (317-274-7677, findt1d@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rates of Returned Home Screening Kits (time frame: From enrollment to the end of study at 3 years.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.